MVA RH5

Phase 2Biologic

BBarinthus Biotherapeutics

MVA RH5 is one of 110 biologic programs targeting Plasmodium falciparum malaria. It is currently in Phase 2.

Indications

Total Trials

Active Trials

109

Competitors

Pipeline

Status by Indication[3][1]

Indication

Plasmodium Falciparum MalariaActive, not recruiting

MalariaActive, not recruiting

InfluenzaActive, not recruiting

TuberculosisActive, not recruiting

Plasmodium Falciparum MalariaPhase 1

Active, not recruiting

MalariaPhase 1/Phase 2

Active, not recruiting

InfluenzaPhase 2

Active, not recruiting

TuberculosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

MVA RH5

BBarinthus Biotherapeutics

Phase 2

7 2

Fluzone

Sanofi

Preclinical

16 3

Fluzone

GSK

Preclinical

37 4

Trexall

Alnylam Pharmaceuticals

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 8

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 9

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

14 10

PD-1/PD-L1 Inhibitors

CChuangzhen Chen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Influenza7 trials

A Phase I Study of Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1

Completed·UUniversity of Oxford·Phase 1·NCT01818362·72 enrolled

Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model

Completed·BBarinthus Biotherapeutics·Phase 2·NCT03883113·145 enrolled

A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy Adults

Completed·UUniversity of Oxford·Phase 1·NCT00942071·58 enrolled

Show 4 more trials

Improved Novel VaccIne CombinaTion InflUenza Study

Terminated·BBarinthus Biotherapeutics·Phase 2·NCT03300362·862 enrolled

A Study to Assess the Safety and Efficacy of a New Influenza Candidate Vaccine MVA-NP+M1 In Healthy Adults

Completed·UUniversity of Oxford·Phase 2·NCT00993083·27 enrolled

A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1

Completed·BBarinthus Biotherapeutics·Phase 1·NCT03277456·6 enrolled

Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults

Terminated·BBarinthus Biotherapeutics·Phase 2·NCT03880474·2,364 enrolled

Immunogenicity6 trials

Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines

Completed·UUniversity of Oxford·Phase 1·NCT00480454·214 enrolled

A Study to Determine the Safety and Immunogenicity of a Candidate MAP Vaccines ChAdOx2 HAV and MVA in Healthy Adult Volunteers

Completed·UUniversity of Oxford·Phase 1·NCT03027193·28 enrolled

The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV

Completed·UUniversity of Oxford·Phase 1·NCT00395720·20 enrolled

Show 3 more trials

Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB.

Completed·UUniversity of Oxford·Phase 1·NCT00456183·12 enrolled

Safety and Immunogenicity of MVA85A, in Healthy Volunteers in Cape Town

Completed·UUniversity of Oxford·Phase 1·NCT00460590·36 enrolled

Safety and Immunogenicity of ChAd63 RH5 and MVA RH5 in Adults, Young Children and Infants Living in Tanzania

Completed·UUniversity of Oxford·Phase 1·NCT03435874·63 enrolled

Malaria5 trials

Malaria Infection Diagnosed by Polymerase Chain Reaction (PCR) as a Means of Evaluating Pre-erythrocytic Candidate Malaria Vaccines

Completed·LLondon School of Hygiene and Tropical Medicine·Phase 1/2·NCT00121823·120 enrolled

A Clinical Trial to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313

Completed·UUniversity of Oxford·Phase 1·NCT02532049·26 enrolled

A Study to Assess the Effectiveness of a New Malaria Vaccine Candidate by Infecting Vaccinated Volunteers With Malaria Parasites

Completed·UUniversity of Oxford·Phase 1/2·NCT00890760·55 enrolled

Show 2 more trials

A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches Using the ChAd63 and MVA Vectors Encoding the Antigens ME-TRAP, CS and AMA1

Completed·UUniversity of Oxford·Phase 1/2·NCT01739036·48 enrolled

A Study to Assess the Safety and Immunogenicity of a Candidate Malaria Vaccine Using Novel Routes of Administration

Completed·UUniversity of Oxford·Phase 1·NCT03084289·26 enrolled

Safety and Efficacy4 trials

A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S

Completed·UUniversity of Oxford·Phase 1/2·NCT02252640·48 enrolled

A Safety and Efficacy Study of R21 +/- ChAd63/MVA ME-TRAP

Completed·UUniversity of Oxford·Phase 1/2·NCT02905019·63 enrolled

A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S

Completed·UUniversity of Oxford·Phase 1/2·NCT01883609·48 enrolled

Show 1 more trial

A Safety and Efficacy Study of ChAdOx1 LS2 and MVA LS2

Completed·UUniversity of Oxford·Phase 1/2·NCT03203421·18 enrolled

Efficacy2 trials

Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults

Not yet recruiting·UUniversity Hospital Tuebingen·Phase 1/2·NCT05441410·30 enrolled

Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost Regimen

Completed·UUniversity of Oxford·Phase 1/2·NCT00408668·30 enrolled

5 more indications

Tuberculosis1 trial

Safety of Tuberculosis Vaccine, MVA85A, Administered by the Intramuscular Route and the Intradermal Route

Completed·UUniversity of Oxford·Phase 1·NCT01181856·24 enrolled

Plasmodium falciparum malaria1 trial

A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5

Completed·UUniversity of Oxford·Phase 1·NCT02181088·26 enrolled

HIV1 trial

A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both

Completed·UUniversity of Oxford·Phase 1·NCT00480558·48 enrolled

Vaccine1 trial

A Study of 2 Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCG

Completed·UUniversity of Oxford·Phase 1·NCT00465465·24 enrolled

Unspecified1 trial

Phase Ia Study of ChAd63/MVA PvDBP

Completed·UUniversity of Oxford·Phase 1·NCT01816113·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 29 trial records for MVA RH5. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MVA RH5 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MVA RH5. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Barinthus Biotherapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: BBarinthus Biotherapeutics

MVA RH5

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Influenza7 trials

Immunogenicity6 trials

Malaria5 trials

Safety and Efficacy4 trials

Efficacy2 trials

Tuberculosis1 trial

Plasmodium falciparum malaria1 trial

HIV1 trial

Vaccine1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News